Podcasts | Accessible conversations on pharma's hot topics

R&D

pharmaphorum podcast Episode 267, Haseeb Ahmad - Purespring Therapeutics

Purespring on nephrology & gene therapy in kidney disease

Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

pharmaphorum podcast Episode 265, Leonard Mazur, Citius

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Oncology

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Patients

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Pushing through barriers to commercial launch success, with ...

In this sponsored pharmaphorum podcast, Amanjeet Singh Saluja, a Principal at Axtria, discusses the current state of affairs in launch success.

Digital

pharmaphorum podcast Episode 261 - Kris Kaneta, Norstella

Trustworthy and novel AI in clinical trial planning, with Kr...

Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials

Digital

BIO-Europe Spring podcast with Kashif Sadiq

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Oncology

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.